Net loss for the six months ended January 31, 2026, was $(472,231), a significant increase from $(233,185) for the same period in 2025. Research and development expenses increased to $433,307 for the six months ended January 31, 2026, up from $130,023 in 2025. General and administrative expenses slightly decreased to $64,636 for the six months ended January 31, 2026, from $80,012 in 2025. Acquired an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer from BriaCell Therapeutics Corp. BriaCell has agreed to make available a credit facility of up to $3,000,000 to fund research and development activities related to sCD80. Issued 23,972,589 common shares to BriaCell with an aggregate value of approximately C$1.18 million, increasing BriaCell's ownership interest in BriaPro to approximately 78%. Reported a negative working capital of $1,638,799 as of January 31, 2026, worsening from $1,148,492 on July 31, 2025. Accumulated deficit since incorporation reached $1,652,656. The company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and obtain necessary financing. Jamieson Bondarenko was appointed as Chairman to the BriaPro board on March 30, 2026.